title: The therapeutic effect on bone mineral formation from biomimetic zinc containing tricalcium phosphate (ZnTCP) in zinc-deficient osteoporotic mice.
abstract: The aim of this study was to evaluate the therapeutic efficacy of biomimetic zinc-containing tricalcium phosphate (ZnTCP) produced by hydrothermally converting calcium carbonate exoskeletons from foraminifera, in the treatment of osteoporotic mice. X-Ray powder diffraction showed crystallographic structures matching JCPDS profile for tricalcium phosphate. Mass spectroscopy used to calculate total composition amount showed similar amount of calcium (5×10(4) µg/g) and phosphate (4×10(4) ppm) after conversion and the presence of zinc (5.18×10(3) µg/g). In vitro zinc release showed no release in PBS buffer and <1% zinc release in 7 days. In vivo evaluation was done in ovariectomized mice by implanting the ZnTCP samples in the soft tissues near the right femur bone for four weeks. Thirty ddY mice (5 weeks old, average weight of 21 g) were divided into six experimental groups (normal, sham, OVX, β-TCP, ZnTCP and direct injection of zinc). CT images were taken every two weeks where the bone mineral density (BMD) and bone mineral content (BMC) were calculated by software based on CT images. The ZnTCP group exhibits cortical and cancellous bone growth of 45% and 20% respectively. While sham, OVX and β-TCP suffered from bone loss. A correlation was made between the significant body weight increase in ZnTCP with the significant increase in plasma zinc level compared with OVX. The presented results indicate that biomimetic ZnTCP were effective in preventing and treating bone loss in osteoporotic mice model.
authors: Faculty of Pharmacy, Research Institute of Pharmaceutical Science, Musashino University, Nishi-Tokyo, Japan. Joshua.chou@uts.edu.au
authors: Joshua
authors: J
authors: Chou
authors: Jia
authors: J
authors: Hao
authors: Hirokazu
authors: H
authors: Hatoyama
authors: Besim
authors: B
authors: Ben-Nissan
authors: Bruce
authors: B
authors: Milthorpe
authors: Makoto
authors: M
authors: Otsuka
mesh_terms: D000818:Animals; D001835:Body Weight / Q000187:drug effects; D015519:Bone Density; D002113:Calcification, Physiologic / Q000187:drug effects*; D002130:Calcium Phosphates / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D005260:Female; D051379:Mice; D018716:Molecular Mimicry; D010024:Osteoporosis / Q000188:drug therapy / Q000378:metabolism*; D015032:Zinc / Q000008:administration & dosage / Q000097:blood / Q000172:deficiency*
chemical_list: D002130:Calcium Phosphates; D015032:Zinc; C018392:tricalcium phosphate
references: Biochem Pharmacol. 1994 Sep 15;48(6):1225-30
references: 7945416
references: Mol Cell Biochem. 1993 May 12;122(1):59-64
references: 8350864
references: Acta Biomater. 2009 Jan;5(1):508-17
references: 18644755
references: Bone. 2008 Jan;42(1):129-38
references: 17945546
references: Biol Pharm Bull. 2011;34(8):1215-8
references: 21804208
references: J Biomed Mater Res. 2000 May;50(2):184-90
references: 10679683
references: Biomaterials. 2010 May;31(14):3949-56
references: 20170952
references: J Biomed Mater Res A. 2004 Jun 1;69(3):552-60
references: 15127402
references: Biomed Mater Eng. 2003;13(2):103-13
references: 12775901
references: Nanomedicine (Lond). 2014;9(8):1131-9
references: 24471502
references: Am J Clin Nutr. 2004 Sep;80(3):715-21
references: 15321813
references: Endeavour. 1984;8(2):65-70
references: 6204848
references: Nature. 1974 Jan 25;247(5438):220-2
references: 4149289
references: PLoS One. 2013;8(1):e54676
references: 23349949
references: J Biomed Mater Res. 2000 Dec 15;52(4):819-24
references: 11033565